H.C. Wainwright maintains $75 target on Corbus stock

On Monday, H.C. Wainwright analyst Andres Y. Maldonado confirmed a Buy rating and a $75.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside potential from the current price of $10.15. With a market capitalization of $124 million, CRBP has garnered strong analyst support, maintaining a consensus "Strong Buy" recommendation according to InvestingPro data. Maldonado’s endorsement comes in anticipation of the company’s update on CRB-701 at the ASCO GU 25 symposium on February 14. The firm recently conducted a virtual KOL investor event focusing on the development of novel antibody-drug conjugates (ADCs) for treating gynecological cancers, which included insights from a prominent gynecologic oncologist.

During the event, the oncologist highlighted the potential of next-generation ADCs, particularly noting CRB-701’s broad applicability in various tumor types beyond urothelial carcinoma. The discussion underscored CRB-701’s unique linker technology, which may overcome some limitations of existing ADCs. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 13.84, providing runway for continued development. The upcoming ASCO GU 25 update is expected to present data from at least 12 patients spanning multiple dose cohorts, ranging from 1.8 to 4.5 mg/kg.

A successful dataset could show CRB-701’s safety benefits compared to Pfizer (NYSE:PFE)’s Padcev, especially in terms of lower instances of peripheral neuropathy and skin toxicity. This would be consistent with previous ex-US findings. While the efficacy results, including a 44% objective response rate (ORR) in urothelial carcinoma and a 43% ORR in cervical cancer, are promising, Maldonado advises a cautious approach to interpreting these early-stage efficacy data.

In conclusion, Maldonado reiterated his positive stance on Corbus Pharmaceuticals, emphasizing the key points from the KOL discussion that support the potential of CRB-701. The Buy rating and $75 price target remain unchanged as the market looks forward to the detailed update at the upcoming symposium. According to InvestingPro, the stock appears undervalued based on its Fair Value analysis, despite showing high volatility with a beta of 2.63. Investors can access 8 additional ProTips and comprehensive financial analysis through InvestingPro’s detailed research report, available for over 1,400 US stocks.

In other recent news, Corbus Pharmaceuticals has been making significant strides in its drug development efforts. Mizuho (NYSE:MFG) Securities has maintained its Outperform rating for Corbus, citing encouraging outlooks for the company’s drug candidate CRB-701, particularly following disappointing clinical data from a competitor. Piper Sandler also initiated coverage on Corbus with an Overweight rating, highlighting the potential of CRB-701 in treating solid tumors, including cervical cancer.

In addition, Corbus has launched a Phase 1 clinical trial for its drug candidate CRB-601, designed for patients with advanced solid tumors. This development marks a significant milestone in the company’s ongoing efforts to advance the understanding of immunotherapy treatments.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Corbus’ investigational drug, CRB-701, for the treatment of relapsed or refractory metastatic cervical cancer. This designation underlines the potential of CRB-701 to address unmet medical needs in serious conditions.

On the corporate front, Corbus Pharmaceuticals board member, Anne Altmeyer Ph.D., has initiated a prearranged trading plan for her shares in the company. This move aligns with standard financial practices and legal frameworks governing the trading activities of corporate insiders. These are recent developments that underscore the company’s commitment to innovative scientific approaches to treat serious illnesses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.